LXRX vs SNDX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LXRX · Lexicon Pharmaceuticals$1.78 ▲ 10.56%
SNDX · Syndax Pharmaceuticals$9.54 ▲ 1.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LXRX +25.4%
- SNDX -39.3%
Head to head
| Metric | LXRX | SNDX |
|---|---|---|
| Price | $1.78 | $9.54 |
| Change today | ▲ 10.56% | ▲ 1.81% |
| Market cap | $792.52M | $858.87M |
| Return, 3 months | -25.8% | -53.2% |
| Return, year to date | +54.8% | -54.6% |
| Return, 1 year | +42.4% | -36.6% |
| P/E (TTM) | – | – |
| P/B | 4.8 | -49.9 |
| P/E percentile vs own 5y | 16th | 56th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -97.6% | +91.8% |
| Net profit growth (YoY) | -1,077.1% | +31.3% |
| Gross margin | 99.1% | 95.8% |
| Operating margin | -131.4% | -77.0% |
| Net margin | -147.4% | -87.5% |
| Return on equity | -40.2% | -255.9% |
| Analyst target vs. price | +224.7% | +301.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 61 | 26 |
| 30-day volatility | 60.9% | 114.7% |
| Max drawdown, 1 year | -46.2% | -62.7% |
| Trend read | Mixed | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SNDX is the largest of the group by market value.
- LXRX has returned the most over the past year.
- SNDX is growing revenue fastest.
- SNDX keeps the most profit per dollar of sales.
- LXRX has been the calmest stock over the last 30 days.